News
Current position:Product Center > Antibodies > Biosimilar Antibodies > Anti-CD20 hIgG1 Reference Antibody (Ritubio)
Anti-CD20 hIgG1 Reference Antibody (Ritubio)
Product Info

Cat. No:GM-87804MAB

Product:Anti-CD20 hIgG1 Reference Antibody (Ritubio)


Cat. No & Size

GM-87804MAB-1mg / 1 mg

GM-87804MAB-5mg / 5 mg

GM-87804MAB-25mg / 25 mg

GM-87804MAB-50mg / 50 mg

GM-87804MAB-100mg / 100 mg


Description

Expression System      CHO

Aggregation                < 5% as determined by SEC-HPLC

Purity                           > 95% as determined by SDS-PAGE

Endotoxin                    < 1 EU/mg, determined by LAL gel clotting assay

Sterility                        0.2 μm Filtered

Target                          CD20

Clone                               Rituximab

Alternative Names         B1, Bp35, CVID5, FMC7, LEU-16, S7

Source/Isotype           Human  hIgG1(KDEL), Kappa

Application                      /

Description                 B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. Immunohistochemistry can be used to determine the presence of CD20 on cells in histological tissue sections. Because CD20 remains present on the cells of most B-cell neoplasms,and is absent on otherwise similar appearing T-cell neoplasms, it can be very useful in diagnosing conditions such as B-cell lymphomas and leukaemias. However, the presence or absence of CD20 in such tumours is not relevant to prognosis, with the progression of the disease being much the same in either case. CD20 positive cells are also sometimes found in cases of Hodgkins disease, myeloma, and thymoma.

Formulation                phosphate-buffered solution, pH 7.4.



Data

image.png

image.png


Current position:Product Center > -- > Anti-CD20 hIgG1 Reference Antibody (Ritubio)
classify
Anti-CD20 hIgG1 Reference Antibody (Ritubio)
Product Info

Cat. No:GM-87804MAB

Product:Anti-CD20 hIgG1 Reference Antibody (Ritubio)


Cat. No & Size

GM-87804MAB-1mg / 1 mg

GM-87804MAB-5mg / 5 mg

GM-87804MAB-25mg / 25 mg

GM-87804MAB-50mg / 50 mg

GM-87804MAB-100mg / 100 mg


Description

Expression System      CHO

Aggregation                < 5% as determined by SEC-HPLC

Purity                           > 95% as determined by SDS-PAGE

Endotoxin                    < 1 EU/mg, determined by LAL gel clotting assay

Sterility                        0.2 μm Filtered

Target                          CD20

Clone                               Rituximab

Alternative Names         B1, Bp35, CVID5, FMC7, LEU-16, S7

Source/Isotype           Human  hIgG1(KDEL), Kappa

Application                      /

Description                 B-lymphocyte antigen CD20 or CD20 is expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. In humans CD20 is encoded by the MS4A1 gene. This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule that plays a role in the development and differentiation of B-cells into plasma cells. Immunohistochemistry can be used to determine the presence of CD20 on cells in histological tissue sections. Because CD20 remains present on the cells of most B-cell neoplasms,and is absent on otherwise similar appearing T-cell neoplasms, it can be very useful in diagnosing conditions such as B-cell lymphomas and leukaemias. However, the presence or absence of CD20 in such tumours is not relevant to prognosis, with the progression of the disease being much the same in either case. CD20 positive cells are also sometimes found in cases of Hodgkins disease, myeloma, and thymoma.

Formulation                phosphate-buffered solution, pH 7.4.



Data

image.png

image.png


Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit